细胞质中 maspin 的表达是肿瘤大小<3 cm 的肺腺癌患者预后不良的一个预测指标。

Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring <3 cm.

作者信息

Takagi Yuzo, Matsuoka Yuki, Shiomi Tatsushi, Nosaka Kanae, Takeda Chikako, Haruki Tomohiro, Araki Kunio, Taniguchi Yuji, Nakamura Hiroshige, Umekita Yoshihisa

机构信息

Division of Organ Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Tottori, Japan; Division of General Thoracic Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Tottori, Japan.

出版信息

Histopathology. 2015 Apr;66(5):732-9. doi: 10.1111/his.12586. Epub 2014 Dec 22.

DOI:10.1111/his.12586

PMID:25322663

Abstract

AIMS

Maspin is known to be a tumour suppressor protein, and few studies focused upon its prognostic significance in patients with small-size lung adenocarcinoma have been reported; however, its clinical significance remains controversial. We explored the prognostic value of maspin with particular reference to its subcellular localization in patients with resected lung adenocarcinoma measuring <3 cm.

METHODS AND RESULTS

Immunohistochemical analyses were performed on resected 110 specimens of lung adenocarcinoma measuring <3 cm. Maspin positivity was defined as strong expression in only the cytoplasm and was observed in 27 patients (24.5%). It correlated significantly with the presence of lymph node metastasis (P = 0.009) and micropapillary component (P < 0.001). The patients were followed-up for 6-88 months (median: 71 months), and the maspin-positive group had shorter disease-free survival (DFS) and overall survival (OS) by log-rank test (P < 0.001, P < 0.001, respectively). Using Cox's multivariate analysis, the status of maspin was an independent prognostic factor for DFS and OS (P = 0.004, P = 0.022, respectively), as well as lymph node metastasis.

CONCLUSIONS

Cytoplasmic maspin expression could be an independent poor prognostic indicator of patients with lung adenocarcinoma measuring <3 cm.

摘要

目的

已知乳腺丝抑蛋白是一种肿瘤抑制蛋白，然而针对其在小尺寸肺腺癌患者中的预后意义的研究报道较少，其临床意义仍存在争议。我们探讨了乳腺丝抑蛋白的预后价值，特别关注其在切除的直径<3 cm的肺腺癌患者中的亚细胞定位。

方法与结果

对110例切除的直径<3 cm的肺腺癌标本进行免疫组织化学分析。乳腺丝抑蛋白阳性定义为仅在细胞质中强表达，在27例患者（24.5%）中观察到。它与淋巴结转移的存在（P = 0.009）和微乳头成分（P < 0.001）显著相关。患者随访6 - 88个月（中位时间：71个月），通过对数秩检验，乳腺丝抑蛋白阳性组的无病生存期（DFS）和总生存期（OS）较短（分别为P < 0.001，P < 0.001）。使用Cox多因素分析，乳腺丝抑蛋白状态是DFS和OS的独立预后因素（分别为P = 0.004，P = 0.022），以及淋巴结转移。